My ePortfolio Register   

The DNA damage response and cancer therapy

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.01.15
Views: 3079

Dr Christopher Lord, The Institute of Cancer Research, London, UK

Dr Lord talks to ecancer at the 2nd EurocanPlatformTranslational Research Course, discussing his work on the concept of ‘synthetic lethality’, PARP inhibitors and the lessons his lab have learned whilst developing new approaches to treating cancer.

He also covers the obstacles facing this work and how it could impact clinical practise.

Learn more about the EurocanPlatform project here

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence